Literature DB >> 11187921

Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995.

M Tsuchida1, K Ikuta, R Hanada, T Saito, K Isoyama, K Sugita, Y Toyoda, A Manabe, K Koike, A Kinoshita, M Maeda, K Ishimoto, T Sato, Y Okimoto, T Kaneko, M Kajiwara, M Sotomatsu, Y Hayashi, H Yabe, R Hosoya, Y Hoshi, M Ohira, F Bessho, Y Tsunematsu, I Tsukimoto, S Nakazawa.   

Abstract

The objectives were as follows: Firstly, to estimate the overall probability of event-free survival (EFS) and isolated CNS relapse in the studies for children with acute lymphoblastic leukemia (ALL) during the 1980s and 1990s. Secondly, to report the EFS according to presenting features and lineage. Thirdly, to evaluate the treatment results re-classified by the risks of NCI criteria. Four consecutive protocol studies were performed in the Tokyo Children's Cancer Study Group: L81-10 protocol (1981-1984, 189 patients), L84-11 (1984-1989, 484 patents), L89-12 (1989-1992, 418 patients) and L92-13 (1992-1995, 347 patients). Overall EFS at 5 years in each protocol was 56.5 +/- 3.8(1 s.e.)%, 71.0 +/- 2.1%, 67.8 +/- 2.3%, and 63.4 +/- 2.7%, respectively. The cumulative isolated CNS relapse rate at 5 years was 8.1 +/- 2.1%, 3.5 +/- 0.9%, 3.6 +/- 1.0%, 1.0 +/- 0.6. The EFS in SR/HR (standard risk/high risk) according to the NCI criteria in B-precursor ALL at 5 years was 61.9 +/- 4.3%/41.4 +/- 7.4% (lineage was not confirmed.), 72.5 +/- 2.6%/63.4 +/- 5.0%, 77.4 +/- 2.7%/56.3 +/- 4.7%, and 67.8 +/- 3.4%/56.7 +/- 5.4% in each protocol. Also EFSs according to NCI SR/HR at 5 years of T-ALL in protocols L84-11, L89-12 and L92-13 were 55.6 +/- 16.6%/60.9 +/- 10.1%, 72.7 +/- 13.4%/51.6 +/- 9.1%, and 77.1 +/- 14.4%/53.6/10.1%, respectively. The truncation of maintenance therapy to 6 months resulted in a decreased EFS in L92-13, particularly due to an increase of bone marrow relapse after cessation of therapy in SR and HR. The NCI risk criteria work properly even in the patients treated by different intensities, so that it makes the comparison possible among the patients in various groups. The overall EFSs in childhood ALL improved in 1980s, but it seemed stable or decreased in 1990s. The short maintenance therapy resulted in poor outcome in SR on the L92-13 protocol. Many of these late relapsers were effectively rescued and overall survival remained at a high level. The proportion of patients who received cranial irradiation reduced without any increase of the CNS events.

Entities:  

Mesh:

Year:  2000        PMID: 11187921     DOI: 10.1038/sj.leu.2401937

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  International collaboration on childhood leukemia.

Authors:  Ching-Hon Pui; Raul C Ribeiro
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Induction of impaired membrane phospholipid asymmetry in mature erythrocytes after chemotherapy.

Authors:  Xiaochun Zhang; Takeshi Inukai; Kinuko Hirose; Koshi Akahane; Atsushi Nemoto; Kazuya Takahashi; Hiroki Sato; Keiko Kagami; Kumiko Goi; Kanji Sugita; Shinpei Nakazawa
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups.

Authors:  Masahito Tsurusawa; Keiko Yumura-Yagi; Akira Ohara; Junichi Hara; Naoyuki Katano; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 4.  Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.

Authors:  Nobuko Hijiya; Kirsten K Ness; Raul C Ribeiro; Melissa M Hudson
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

5.  Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998.

Authors:  Isabel Badell; Arturo Muñoz; Jesús Estella; Rafael Fernández-Delgado; Germán Javier; Amparo Verdeguer; Josep Cubells
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

6.  Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UK.

Authors:  R G Feltbower; S E Kinsey; M Richards; G Shenton; M P Michelagnoli; P A McKinney
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

7.  The evolution of clinical trials for infant acute lymphoblastic leukemia.

Authors:  R S Kotecha; N G Gottardo; U R Kees; C H Cole
Journal:  Blood Cancer J       Date:  2014-04-11       Impact factor: 11.037

8.  Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia.

Authors:  David T Teachey; Stephen P Hunger; Mignon L Loh
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.